SG174111A1 - NOVEL ß-GLUCANS ISOLATED FROM HIGHER BASIDIOMYCETES MUSHROOM GANODERMA TSUGAE VAR. JANNIEAE - Google Patents
NOVEL ß-GLUCANS ISOLATED FROM HIGHER BASIDIOMYCETES MUSHROOM GANODERMA TSUGAE VAR. JANNIEAE Download PDFInfo
- Publication number
- SG174111A1 SG174111A1 SG2010054831A SG2010054831A SG174111A1 SG 174111 A1 SG174111 A1 SG 174111A1 SG 2010054831 A SG2010054831 A SG 2010054831A SG 2010054831 A SG2010054831 A SG 2010054831A SG 174111 A1 SG174111 A1 SG 174111A1
- Authority
- SG
- Singapore
- Prior art keywords
- glucan
- composition
- var
- jannieae
- ganoderma tsugae
- Prior art date
Links
- 241001480597 Ganoderma tsugae Species 0.000 title claims abstract description 76
- 229920001503 Glucan Polymers 0.000 title claims description 167
- 235000001674 Agaricus brunnescens Nutrition 0.000 title abstract description 78
- 241000221198 Basidiomycota Species 0.000 title abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 239000000047 product Substances 0.000 claims abstract description 32
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 16
- 239000002417 nutraceutical Substances 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 26
- 108010057466 NF-kappa B Proteins 0.000 claims description 14
- 102000003945 NF-kappa B Human genes 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000000638 stimulation Effects 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000008184 oral solid dosage form Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000007894 caplet Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 230000002641 glycemic effect Effects 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 51
- 239000002028 Biomass Substances 0.000 abstract description 38
- 229920002498 Beta-glucan Polymers 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 58
- 150000004676 glycans Chemical class 0.000 description 54
- 229920001282 polysaccharide Polymers 0.000 description 54
- 239000005017 polysaccharide Substances 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 230000000694 effects Effects 0.000 description 41
- 239000008103 glucose Substances 0.000 description 27
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 26
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 25
- 229940069510 parthenolide Drugs 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 150000002772 monosaccharides Chemical group 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 238000009835 boiling Methods 0.000 description 17
- 238000000605 extraction Methods 0.000 description 17
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 17
- 230000000259 anti-tumor effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 12
- 241000233866 Fungi Species 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 12
- 229920000057 Mannan Polymers 0.000 description 11
- 239000002054 inoculum Substances 0.000 description 11
- 230000011987 methylation Effects 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 240000008397 Ganoderma lucidum Species 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 241000222481 Schizophyllum commune Species 0.000 description 9
- 238000005571 anion exchange chromatography Methods 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241000222336 Ganoderma Species 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- -1 galactan Polymers 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 7
- 229920001491 Lentinan Polymers 0.000 description 7
- 240000000599 Lentinula edodes Species 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 229930182830 galactose Natural products 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229940115286 lentinan Drugs 0.000 description 7
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 101150091206 Nfkbia gene Proteins 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 235000010419 agar Nutrition 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229960002442 glucosamine Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
- 241000222355 Trametes versicolor Species 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 238000005852 acetolysis reaction Methods 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229960003082 galactose Drugs 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 4
- 235000001715 Lentinula edodes Nutrition 0.000 description 4
- 241000565614 Leucocoprinus birnbaumii Species 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000003468 luciferase reporter gene assay Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000123330 Fomes fomentarius Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 241001452792 Tricholomopsis sulphureoides Species 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000036815 beta tubulin Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 150000002402 hexoses Chemical group 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000009965 odorless effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 241001475335 Ganoderma sp. Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 241000222341 Polyporaceae Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229920002305 Schizophyllan Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000001727 Tropicoporus linteus Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 108010025838 dectin 1 Proteins 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 108010001062 polysaccharide-K Proteins 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001551 total correlation spectroscopy Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241000221702 Aleuria Species 0.000 description 1
- 241000615866 Antho Species 0.000 description 1
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 244000234623 Coprinus comatus Species 0.000 description 1
- 235000004439 Coprinus comatus Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000170036 Endosporium Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 241001480612 Ganoderma resinaceum Species 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000838578 Homo sapiens Serine/threonine-protein kinase TAO2 Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000414067 Inonotus obliquus Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 244000028178 Marasmius oreades Species 0.000 description 1
- 235000017233 Marasmius oreades Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 239000001083 [(2R,3R,4S,5R)-1,2,4,5-tetraacetyloxy-6-oxohexan-3-yl] acetate Substances 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003818 cinder Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002029 lignocellulosic biomass Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 229940034049 polysaccharide-k Drugs 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009219 proapoptotic pathway Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/271—Curdlan; beta-1-3 glucan; Polysaccharides produced by agrobacterium or alcaligenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Novel highly soluble in water β-glucan is provided that can be obtainedfrom the fruiting bodies or the submerged cultivated mycelium biomass of thehigher Basidiomycetes medicinal mushroom Ganoderma tsugae var. jannieaestrain Tay-1. Also provided are compositions comprising the β-glucanfor use as nutriceuticals, dietary supplements, cosmetic products, and in therapy.
Description
) 4
NOVEL B-GLUCANS ISOLATED FROM HIGHER BASIDIOMYCETES
MUSHROOM GANODERMA TSUGAE VAR. JANNIEAE
The present invention relates to polysaccharides isolated from mushrooms and, more particularly, to novel highly soluble in water B-glucan isolated from the higher Basidiomycetes medicinal mushroom variety designated Ganoderma tsugae var. jannieae and, particularly, from a new and distinct strain thereof designated
Ganoderma tsugae var. jannieae strain Tay-1.
~, Mushrooms or macrofimgi represent a major and, as yet, largely untapped source of potent new pharmaceutical products. Of approximately 15000 known species, 2000 are safe for people's health, and about 650 of them possess medicinal properties (Wasser, 2002).
Edible and medicinal mushrooms (macrofungi) not only can convert the huge lignocellulosic biomass waste into human food but, most remarkably, can produce notable mycopharmaceuticals, myconutriceuticals : and myco- cosmeceiiticals.
The most significant aspect of mushroom cultivation, if managed properly, is to créate zero emission of lignocellulosic waste materials. Mushroom biotechnological products have multibeneficial effects to human welfare, e.g., as food, health tonics and medicine, feed and fertilizers, and to protect and regenerate the environment. Pharmaceutical substances with potent and unique health- enhancing properties were isolated recently from medicinal mushrooms and distributed worldwide (Mizuno, 1999; Wasser and Weis, 1999; Borchers et al.,
2004; Lindequist et al., 2005; Sullivan et al., 2006; Moradali et al., 2007). Many of them are pharmaceutical products, while others represent a novel class of dietary supplements (Wasser et al., 2004) or "mushroom nutraceuticals" (Chang and
Buswell, 2003). Several antitumor polysaccharides, such as hetero-p-glucans and their protein complexes (e.g., xyloglucans, and acidic p-glucan containing uronic 1 acid) as well as dietary fiber, lectins, and triterpenoids, have been isolated from medicinal mushrooms. The potential of medicinal mushrooms is enormous but mostly untapped. It could and should evolve into a successful biotechnological industry for the benefit of humankind.
Medicinal mushroom mycology has deep and firm roots in fungi's traditional uses in the medicine of the Far East. For centuries, Chinese and other healthcare practitioners employed mushrooms to treat various diseases. Only at the end of the 1960s did Eastern and Western scientists start to investigate the mechanisms of the health effects of mushrooms. The first successful research discovered the antitumor effects of hot water extracts from several mushroom species. The main active components proved to be polysaccharides, specifically $-D-glucans (Chen and
Seviour, 2007). Chihara and his co-workers (1969) isolated from the fruiting bodies of shiitake mushroom (Lentinus edodes) a water-soluble antitumor polysaccharide, which was named "lentinan" after the generic name of this mushroom and demonstrated powerful antitumor activity, preventing chemical and viral tumor development in mice and experimental models (Mizuno, 1999).
Mushroom Polysaccharides
Polysaccharides belong to a structurally diverse class of macromolecules, in which polymers of monosaccharide residues are joined to each other by glycosidic linkages and have the greatest potential for structural variability. The involvement and importance of polysaccharides in tumor and cancer treatment were first recognized more than 100 years ago when it was found that certain polysaccharides could induce complete remission in patients with cancer (Nauts et al., 1946).
Higher Basidiomycetes mushrooms contain a large amount of polysaccharides, :
i especially B-glucans. The literature (Mizuno, 1999; Wasser, 2002b; Chen and
Seviour, 2007; Zhang et al., 2007) suggests f-glucans are affective in treating diseases like cancer, a range of microbial infections, hypercholesterolemia, and diabetes as well as in helping patient recovery from chemotherapy and radiotherapy. B-glucans are also especially beneficial to middle-aged people, people with active and stressful lifestyles, and athletes. The mechanisms of action of B-glucans appear to depend on their capabilities to bind to cell receptors, which are known to include dectin-1, CR3, LacCer, and scavenger receptors. The immune system is stimulated by B-glucans’ presence (Brown and Gordon, 2001, 2005). The anti-tumor effects of B-glucans seem to be related to their molecular weight and solubility. Only the low-molecular weight lentinan, for example, had high anti- tumor activity. Unsurprisingly, soluble f-glucans appear to be stronger immunostimulators than insoluble ones (Wasser, 2002b; Zhang et al., 2005; Chen and Seviour, 2007). However, the relationships between the structures of of the glucans and their stimulatory activities are still controversial due to a lack of reproducible in vitro systems to evaluate the activities of (1—3)-p-D-glucans (Kataoka et al., 2002).
Polysaccharides are the best known and most potent mushroom-derived substances with antitumor and immunomodulating properties. Polysaccharides from mushrooms do not attack cancer cells directly, but produce their antitumor effects by activating different immune responses in the host.
In Japan, China, Russia, and Korea, several different polysaccharide antitumor drugs have been developed from the fruiting bodies, mycelia, and culture media of various medicinal mushrooms, such as shiitake mushroom (Lentinus edodes), ling zhi or reishi (Ganoderma lucidum), turkey tail (Trametes versicolor), split gill (Schizophyllum commune), mulberry yellow polypore (Phellinus linteus), and chaga or cinder conk (Inonotus obliquus).
As mentioned above, lentinan, a 1,3-beta-glucan polysaccharide fraction extracted from Lentinus edodes - shiitake mushroom, was the first polysaccharide extracted from fungi shown to exhibit antitumor activity and was later
Co es - .
commercialized in Japan. Since the discovery of lentinan, several antitumor polysaccharide agents have been developed and commercialized, using the submerged cultured mycelial biomass, including the immunostimulating krestin, polysaccharide-K or PSK, present in a popular Japanese extract made from
Trametes versicolor (also known as Coriolus versicolor) submerged mycelium; the polysaccharide-peptide or PSP, a proteoglycan from Trametes versicolor, widely used in China as anticancer and immunomodulatory agent; and schizophyllan (SPG, sonifilan) a polysaccharide known to suppress tumor growth, especially cervical cancer, extracted from medium product of Schizophyllum commune cultivated in submerged culture.
These antitumor polysaccharides are regarded as biological response modifiers that activate immunological responses. This basically means that they cause no harm and place no additional stress on the body; they help the body to adapt to various environmental and biological stresses; and they have nonspecific action on the body, supporting some or all of the major systems, including nervous, hormonal, and immune systems, as well as regulatory functions.
Mushroom dietary supplements
Mushrooms represent a valuable source of bioactive agents with potent and unique medicinal properties. Most mushroom-derived preparations and substances find their use not as pharmaceutical products (real medicines), but represent a novel class of functional foods, dietary supplements or “nutriceuticals” (Chang and
Buswell, 2003; Wasser et al., 2004).
A mushroom nutraceutical is a refined or partially refined extract or dried biomass from either the mycelium or the fruiting body of the mushroom, which is consumed in the form of capsules or tablets as a dietary supplement (not a conventional food) and which has potential therapeutic applications. Regular intake ~ may enhance the immune responses of the human body, thereby increasing resistance to disease, and in some cases, causing regression of a disease state.
Ganoderma lucidum dietary supplements, for example, are valued for their immunomodulating, anticancer, and antiviral properties and are used during remission of cancer and by hepatitis B patients. They also have anti- hyperlipidemic, hypotensive, and hypoglycemic actions. There are more than 60 brands of Ganoderma lucidum products on the market.
Higher Basidiomycetes mushrooms contain a large amount of polysaccharides, proteins, well-balanced essential amino acids, melanins, lipids comprising essential fatty acids, triterpenoids, antioxidant agents, vitamins, and other biological active substances. Also, dietary fibers belonging to glucans, chitin, and heteropolysaccharides including pectinous substances, hemi-celluloses or polyuronides, are abundant in the tissue of all mushrooms, which are capable of absorbing bile acids or hazardous materials in the intestine, and thus can act as carcinostatics and decrease various kinds of poisoning.
The safety of mushroom-based dietary supplements is enhanced through the following controls: (i) the overwhelming majority of mushrooms used for production of dietary supplements are cultivated commercially (and not gathered in the wild), thus guaranteeing proper identification and pure, unadulterated products, meaning in many cases genetic uniformity; (ii) mushrooms are easily propagated vegetatively and thus keep to one clone, the mycelium can be stored for a long time, and the genetic and biochemical consistency may be checked after a considerable period of time; and (iii) many edible and medicinal mushrooms are capable of growing in the form of mycelial biomass in submerged cultures and thus offer a promising future for standardized production of safe mushroom-based dietary supplements. These are advantages of using mushroom-based dietary supplements as opposed to herbal preparations.
Biological activity of medicinal mushroom substances
Fungal substances are known as modulators of NF-kB activation pathway that plays critical roles in a variety of physiological and pathological processes NF- kB is related to the promotion of cell proliferation, inhibition of apoptosis, and the !
enhancement of tumor metastasis and angiogenesis (Aggarwal, 2004). In addition to its role in activation of immune cells, NF-kB within the malignant cell is a major modulator of the tumor response to inflammation. Inhibition of NF-xB in cancer cells leads inflammation-induced tumor growth to tumor regression. Extracts of several fungi were screened for their ability to interfere with the NF-kB activation pathway. Higher Basidiomycetes mushrooms e.g., Marasmius oreades, Phellinus linteus, and Coprinus comatus as natural sources of low-molecular-weight bioactive substances are able to affect the process of tumorogenesis through the direct blockage of the NF-kB activation at the [kB kinase complex level. Thereview compiles all available data on medicinal mushroom metabolites known tomodulate the activity of NF-kB, thus demonstrating their potential use as novelanti-cancer agents in the rapidly advancing field of molecular therapy, published by
Petrova et al. (2008). Twenty-six species including Ganoderma lucidum werefound to have properties that affected the NF-kB function (Sliva, 2003; Yuen andGohel, 2005; Zaidman et al., 2007; Petrova et al., 2008). 1,3:1,6-B-glucans from fungi, yeast and seaweed as well as 1,3:1,4-B- glucans from grasses express immunostimulatory activity through stimulation of granulocytes (neutrophils and eosinophils), monocytes, macrophages, and natural :killer (NK) cells. Two membrane f-1,3-glucan receptors that mediate biological responses to B-1,3-glucans have been characterized on a molecular level: CR3, expressed on neutrophils, monocytes, and NK cells, and less present on macrophages, and dectin-1, preferentially expressed on macrophages over granulocytes, while absent on NK cells (Hong et al., 2004; Chen and Seviour, 2007). The grass (1,3:1,4)-B-D-glucan consists of an unbranched, unsubstituted glucose chain with two distinct linkage types that are arranged in a non-repeating, but nonrandom, fashion. The (1,3:1,4)-B-D-glucans are components of dietary fibers that are highly beneficial in the prevention and treatment of serious human health conditions, including colorectal cancer, high serum cholesterol and cardiovascular diseases, obesity, and non-insulin-dependent diabetes (Braaten et al., 1994; Brennan et al., 2005; Chen and Seviour, 2007). (1,3:1,4)-p-D-glucans have antinutritive effects in monogastric animals such as pig and poultry (Brennan et al., 1 2005) and are important in many cereal processing applications, including malting and brewing.
Examples of pharmaceutically significant f-glucans exhibiting antitumor activity include grifolan, a p-glucan derived from the fruiting bodies and submerged cultivated mycelia of Grifola fronfosa, maitake mushroom, a higher
Basidiomycetes species (Boh and Berovic, 2007); lentinan, derived from the fruiting bodies of Lentinus edodes (Chichara et al., 1969; Sasaki and Takasuka, 1976); schizophyllan or sonifilan, a B-glucan derived from extract from medium product of Schizophyllum commune cultivated in submerged culture Schizophyllum commune (Kikumoto and Kimura, 1971), used as an immunoadjuvant in the treatment of cancer, especially stomach tumors; and a B-glucan derived from the fruiting bodies of Auricularia auricula-judae , an edible mushroom (Misaki et al., 1981; Hobbs, 1995). These B-glucans bear in common a backbone structure of B- 1,3-linked D-glucopyranose residues with beta-1,6-linked side chains at some of the C-6 positions, and are used as antitumor drugs.
Mushroom constituents are known to have immunomodulatory properties.
The major immunopotentiation effects of these active substances include mitogenicity, stimulation of hematopoietic stem cells, activation of alternative complement pathway, and activation of immune cells such as Ty cells, Tc cells, B cells, macrophages, dendritic cells and NK cells. Different profiles have been observed in relation to the activated immune cells. Some polysaccharides activate B cells and macrophages, but not T cells, while others stimulate all three types of cells. Lentinan is a stimulator of T cells and macrophages, but not of B cells. Some polysaccharides might promote a Ty; response and others a Ty, response. In the particular case of B-glucans, despite the structural and functional similarities of some of them, they differ in their ability to elicit various cellular responses, particularly cytokine expression and production, and in their effectiveness against specific tumors.
Mushroom products are known to affect inflammatory processes.
Macrophages stimulated by mushroom products release several inflammatory cytokines such as IL-1, IL-6, IL-8, TNF- a, and NO, all of which directly induce : tumoricidal activity in macrophages. In other cases mushroom extracts have been shown to assert anti-inflammatory effects by inhibiting the production of NO,
PGE2, IL- 1B, and TNF-a in LPS-stimulated macrophages and LPS administered mice. :
Besides their use as dietary supplements, mushroom-derived preparations may also be used as natural and cosmeceutical products (Wasser et al., 2000, 2001;
Wasser, 2002a; Chang and Buswell, 2003). For example, preparations containing 3- glucans are used in creams to accelerate healing of shallow abrasions and partial thickness burns and as anti-irritant.
Genus Ganoderma
Ganoderma P. Karst. (Ganodermataceae, Polyporales, higher Basidio- mycetes) is a highly distinctive genus of white-rot polypore fungi that is primarily characterized by the formation of a double-walled, generally echinulate, basidiospores. Most Ganoderma species are very variable macromorphologically and lack micromorphological distinctiveness. As a consequence, earlier taxonomic studies in the genus have created many synonymous names and have resulted in largely ambiguous species delimitation and identification systems, making species identification in the genus virtually impossible. Species of Ganoderma used in
Oriental folk medicine refer to “Ling Zhi,” “Chi Zhi,, “Ling Chi,” “Ling Chih,” “Ling Qi,” “Zi Zhi,” “Reishi,” “10,000 year mushroom,” “Herb of spiritual potency,” and “Mushroom of Immortality” in the Chinese literature and have traditionally been labeled G. lucidum in the scientific literature. However, there is now accumulative evidence that most species reported as G. lucidum in most studies were wrongly identified (Moncalvo and Ryvarden, 1997; Moncalvo, 2005;
Wasser et al., 2006).
In recently published illustrations of Ganodermataceae in China, Wu and
Dai (2005) included 77 Ganoderma species. Over the years, at least 166 laccate
Ganoderma species have been described worldwide, of which at least 48 names have been, at some point, considered to be synonyms of others. - In a review on medicinal mushrooms, Wasser (2002b) presented a long list of higher Basidiomycetes mushrooms containing antitumor or immunomodulating polysaccharides, among them 7 Ganoderma species described in the literature. The polysaccharides were found in the fruiting bodies, in the submerged mycelium, and in culture medium of the various species of medicinal mushrooms. As to their chemical structure, the polysaccharides identified in G. lucidum were B-(1—3)- glucuronoglucan and mannogalactoglucan and the polysaccharides identified in G. tsugae were arabinoglucan and glucogalactan.
Wasser (2002b) discloses that polysaccharides have been investigated in both the fruiting bodies and mycelia of Ganoderma tsugae. Seven glycans with strong antitumor activities were obtained from 14 water-soluble and 15 water- insoluble fractions extracted from G. tsugae fruiting bodies (Wang et al., 1993).
Water-soluble fractions were protein-containing glucogalactans associated with mannose and fucose, and water-insoluble fractions represented protein-containing
B-(1—>3)-glucans with different protein content. Sixteen water-soluble : polysaccharides were extracted from G. tsugae mycelium and examined for antitumor effects on Sarcoma 180 in mice (Zhang et al., 1994, 1999). The three active polysaccharides obtained were: a glycan-protein complex containing 9.3% protein, with a heteropolysaccharide composed of mannose and xylose; a glucan- protein complex containing 25.8% protein; and a glycan-protein complex with : glucose as the main component and associated with arabinose, mannose, xylose and galactose. Comparison of active water-soluble polysaccharides obtained from fruiting body and mycelium showed that those from the fruiting body were glucogalactan-protein complexes, but those of the mycelium were homoglucan- protein complexes or a heteroglycan composed of mannose and xylose (Zhang et al., 1994).
Wasser et al. (2006) recently published a study focused on the examination and comparison of wild growing samples of Ganoderma sp. from China, a fungus of the genus Ganoderma, which has very important medicinal properties as a producer of hundreds of biologically active substances. Examination and morphological analysis of the wild growing samples of Ganoderma sp. and their comparison with specimens of Ganoderma lucidum complex, including G. tsugae and G. resinaceum, showed that it is close to G. tsugae but differ in some features from the type of material of G. #sugae. It was then identified as a new variety of the latter taxon, namely, Ganoderma tsugae var. jannieae.
Reference is made to the patent application entitled “New higher
Basidiomycetes medicinal mushroom Ganoderma tsugae var. jannieae strain Tay-1 and biologically active biomass and extracts therefrom”, filed on the same date by same applicant and mentioning the same inventors as in the present application.
The present invention provides a low molecular weight B-glucan composed of a backbone structure of p-1-3- and B-1-4-linked D-glucopyranose residues bearing, at some of the 6-positions, side chains of B-1-6-D-glucopyranose residues, of the structure: :
B-D-Glep-(1-[-6)-B-D-Glep-(1-Jo-1 3-D-Glep(- Joel 418-D-Glp-(1-lor-3)B-D-Glep-(-J-4)-D-Glep-(1-
B-D-Glep-(1-[-6)-B-D-Glep-(1-Jo.1 wherein Glcp represents a glucopyranose residue and n is an integer equal to or larger than 1.
The B-glucan of the invention has a molecular weight lower than 10,000 Da, centered at about or lower than 5,000 Da.
The B-glucan may be obtained from Ganoderma mushroom, particularly from
Ganoderma tsugae and varieties thereof, more particularly from dried fruiting bodies or from submerged cultivated mycelium of the new strain Ganoderma tsugae var. ;
Jannieae strain Tay-1, deposited as a culture with the Centraalbureau voor
Schimmelcultures (CBS), Uppsalalaan 8, P.O. Box 85167, 3508 AD Utrecht, The
Netherlands, on October 23, 2006, under the Budapest Treaty on the International
Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and assigned No. CBS 120394.
The present invention also relates to compositions comprising said B-glucan for use as nutriceuticals or dietary supplements, as an additive to food products or beverages, or for therapy, and to such compositions formulated into food products, beverage products, pet food products, and cosmetic products.
Figs. 1A-1B shows a view from the upper side (Fig. 1A) and a view from the hymenophore (Fig. 1B) of cultivated basidiomata of Ganoderma tsugae var.
Jjannieae.
Fig. 2 shows basidiomata of various shapes (collection from nature) of
Ganoderma tsugae var. jannieae.
Figs. 3A-3B shows Ganoderma tsugae var. jannieae culture in a Petri dish with malt agar medium (Fig. 3A) and staghorn hyphae of vegetative mycelium under scanning electronic microscope (SEM) (Fig. 3B). Scale bar — 10 pm
Fig. 4 shows general methodology for the production of submerged cultured mycelium of Ganoderma tsugae var. jannieae using fermentor or bioreactor : technology: a- preparation of standard agar media for Petri dish; b- spores or parts of fruiting body which are used for preparation of culture; ¢- culture on Petri dish; d- museum culture on agar slant in tube; e- microscopic examination of museum culture; f- pre-inoculums culture in 250 mL Erlenmeyer flask; g- homogenization of pre-inoculums culture; h- cultivation of homogenized mycelial biomass in 2 L - Erlenmeyer flasks; i - homogenization of mycelial biomass for inoculation in fermentor medium; j- growth medium for fermentor; k- cultivation of mycelial biomass in fermentor; l- harvest of mycelial biomass; m- dried biomass formulations for dietary supplements (DS), pharmaceuticals and other products.
Fig. § shows a general view of mycelial pellets of Ganoderma tsugae var.
Jjannieae strain Tay-1 CBS 120394 after 5 days cultivation.
Fig. 6 shows high magnification of the vacuolated hyphae with clamp connections of mycelial pellets of biomass of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394 after 5 days cultivation.
Fig. 7 shows homogenized mycelial pellets of biomass of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394 in a Petri dish before use as inoculums for culturing in a 2 L Erlenmeyer flask.
Fig. 8 shows the mycelial biomass pellets of Ganoderma tsugae var.
Jannieae strain Tay-1 CBS 120394 after 7 days of fungus cultivation in a 2 L
Erlenmeyer flask.
Fig. 9 shows harvested wet mycelial biomass of Ganoderma tsugae var.
Jannieae strain Tay-1 CBS 120394
Fig. 10 shows final product dried pulverized biomass of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394 after fermentation.
Fig. 11 shows vacuolated hyphae with clamp connections of mycelial biomass of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394 after 7 days of fungus cultivation.
Fig. 12 shows a flow chart describing the procedure for isolation of the B- glucan from Ganoderma tsugae var. jannieae fruiting bodies biomass or mycelium.
Fig. 13 depicts the 'H NMR spectrum of purified B-glucan from Ganoderma tsugae var. jannieae mushroom (D,0, 40°) (ppm, parts per million).
Fig. 14 depicts the 'H NMR spectrum of the mixture of the mannan, galactan, and glucan (void volume fraction of Sephadex G50 size exclusion chromatography).
Fig. 15 depicts a gas liquid chromatography-mass spectroscopy (GLC-MS) chromatogram of the methylated alditol acetates obtained from B-glucan. Labels indicate substitution position of the glucose residues in the polymer. Unlabeled peaks could not be positively identified.
! Fig. 16 shows the HSQC (heteronuclear single quantum correlation) and
HMBC (heteronuclear multiple bound correlation) spectra of the B-glucan. Signals of 4,6-di-substituted glucose residues are not visible at this intensity (intensity is reduced for noise removal). "Linked" means that this monosaccharide is linked to an indicated position of the other monosaccharide; "substituted" means that this monosaccharide is substituted by another monosaccharide at the indicated position.
Labels 1-3, 1-4, and 1-6 indicate HMBC correlations between anomeric protons and corresponding transglycosidic carbon atoms. Star marked signals belong to contaminating o-mannan.
Fig. 17 depicts MALDI mass spectrum of B-glucan. Peaks correspond to sodium [M+23]" and potassium [M+39]" adducts. Labels show number of hexose residues in nearest glucose oligomer.
Fig. 18 shows methylation analysis of the B-glucan from Ganoderma tsugae var. jannieae dried fruiting bodies mushroom (lower spectrum) and from submerged cultivated mycelium (upper spectrum). The submerged cultivated mycelium contains less of 4-substituted glucose residues and more of 6- and 3,6- substituted glucose residues. Labels indicate substitution position of the glucose residues in the polymer. T-Glc, terminal glucose.
Fig. 19 depicts 'H NMR spectra of the purified B-glucan (ppm, parts per million). Upper spectrum: glucan in final fraction isolated from dried fruiting bodies; lower spectrum: glucan in final fraction isolated from submerged cultivated mycelium.
Fig. 20 shows reporter inhibition activity of a mycelial diethyl ether extract of Ganoderma tsugae var. jannieae strain Tay-1 (WO01) and of a mycelial ethyl acetate extract of Ganoderma tsugae var. jannieae strain Tay-1 (W02) in MCF7 cancer cell line. Controls: PAR (parthenolide) and MG132, an inhibitor of IxBa degradation.
Fig. 21 shows the effect of different concentrations of the extract of
Canoderma tsugae var. Jannieae strain Tay-1 WO2 on MCF7 cancer cell viability. .
Fig. 22 shows a Western blot analysis on SDS-PAGE separated cancer line proteins specifically probed with anti-IkBa, and anti-tubulin antibodies (control) showing the effect of the mushroom extracts of Ganoderma tsugae var. jannieae strain Tay-1 (WO02), Leucoagaricus birnbaumii (LB12), Tricholomopsis sulphureoides (TS03), Pleurotus ostreatus (POO1), and Schizophyllum commune (SCO1) on IxBa. degradation after 10 min TNF-a stimulation. Extracts were applied to cancer cell lines for 10 minutes and the effect was compared to the effect of 10 minute treatment with TNF-a alone as well as to the effects of controls used, PAR and MG132, respectively. Additionally, the effects of all treatments (extracts and controls) are presented as folds to the beta-tubulin expression. Beta-tubulin is a house-keeping protein, which levels do not vary according to the treatments and, thus, can serve as a control protein representing the accuracy of each experiment provided.
Fig. 23 shows a Western blot analysis on SDS-PAGE separated cancer line proteins specifically probed with anti-pIkBa, antibodies showing the effects of mushroom extracts Canoderma tsugae var. jannieae strain Tay-1 W02 and
Schizophyllum commune SCO1 on IxBa phosphorylation in comparison with 5 minutes TNF-a stimulation. Extracts effect are compared to the effect of TNF-a alone as well as to the effects of controls used, PAR and MG 132, respectively. The level of the house-keeping control protein tubulin is shown in Fig. 19.
Fig. 24 shows the effects of mushroom extracts of Canoderma tsugae var. i
Jannieae strain Tay-1 WO02 and Fomes fomentarius FF04 on cell viability of different cancer cell lines in comparison to the effect of parthenolide (PAR). The concentrations of parthenolide are given in pM, whereas the extracts concentrations are in pg/mL.
In one aspect, the present invention relates to a -glucan having the structure as defined hereinabove.
1 The B-glucan of the invention has a molecular weight of less than 10,000
Da, centered at about or lower than 5,000 Da. In a dried state, the B-glucan is an odorless white powder and it is highly soluble in water producing a brown aqueous solution at high concentrations.
In another aspect, the present invention also relates to a B-glucan having a molecular weight of 5,000-10,000 Da or less, composed of a backbone structure of
B-1-3- and B-1-4-linked D-glucopyranose residues bearing, at some of the 6- positions, side chains of B-1-6-D-glucopyranose residues, which in a dried state is a white odorless powder highly soluble in water producing a brown aqueous solution at high concentrations.
As shown herein in the examples, the B-glucan of the invention has terminal 3-, 4, 3,60 and 4,6-substituted glucose residues in the ratio of 1:0.75:0.25:1.6:0.1:0.6, when subjected to methylation analysis.
The B-glucan of the invention may be obtained, for example, from the higher
Basidiomycetes medicinal mushroom variety Ganoderma tsugae var. jannieae (Wasser et al., 2006). In more preferred embodiments, the B-glucan of the invention is obtained from dried fruiting bodies or from submerged cultivated mycelium of
Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394.
As described herein, several processes can be used for obtaining the B-glucan from the dried biomass of fruiting bodies of Ganoderma tsugae var. jannieae strain
Tay-1 CBS 120394.
According to one embodiment, the B-glucan is obtained from the dried fruiting bodies of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394 by a process comprising the following steps: (i) washing the dried fruiting bodies with ethanol, preferably with boiling 85% ethanol, 3 or more times, and discarding the ethanol extract; (ii) extracting the remainder of the fruiting bodies with boiling water, 5 times or more, subjecting the water extract to dialysis, shaking with a solvent mixture of chloroform and isoamyl alcohol (Sevag protocol), concentrating,
centrifuging, treating the water layer with the same solvent mixture, and freeze- drying to give crude B-glucan that is purified.
According to another embodiment, herein called “alkaline extraction”, the f- glucan is obtained from the dried biomass of fruiting bodies of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394 by a process depicted in Fig. 12 comprising the following steps: (1) washing the dried fruiting bodies with ethanol, preferably with boiling 85% ethanol, 3 or more times, and discarding the ethanol extract; and (ii) extracting the solid remainder of the fruiting bodies with boiling water, 5 times or more, treating (twice) the insoluble residue from water extraction with boiling 5% NaOH-0.05% NaBH,, filtering, neutralizing the alkaline extract with
HCl to a pH of 4, and removing the precipitate by centrifugation; (iii) subjecting the neutralized solution to dialysis, concentration, treatment with a solvent mixture of chloroform and isoamyl alcohol (Sevag protocol), ultracentrifugation and freeze-drying, to give B-glucan of dark brown color that is dissolved in water; (iv) subjecting the brown water solution containing the B-glucan to centrifugation and purification by anion-exchange chromatography, e.g., on a
DEAE cellulose column, and eluting with water followed by 0.25 M NaCl; and (v) recovering the neutral fractions eluted with water and acidic fractions eluted with 0.25 M NaCl, subjecting them to size-exclusion chromatography, e.g., on a Sephadex G-50 column, to give purified B-glucan that is lyophilized (freeze- dried).
According to a further embodiment, herein called “acidic extraction”, the B- glucan is obtained from the dried biomass of fruiting bodies of Ganoderma tsugae var. jannieage strain Tay-1 CBS 120394 by a process comprising the following steps: (i) washing the dried fruiting bodies with ethanol, preferably with boiling 85% ethanol, 3 or more times, and discarding the ethanol extract;
(ii) extracting the solid remainder of the fruiting bodies with boiling water, 5 times or more, treating (twice) the insoluble residue from water extraction with boiling 0.01 M H,80,, filtering, and removing the precipitate by centrifugation; (iii) subjecting the solution to dialysis, concentration, treatment with a solvent mixture of chloroform and isoamyl alcohol (Sevag protocol), ultracentrifugation and freeze-drying, to give B-glucan of light brownish color that is dissolved in water; (iv) subjecting the brown water solution containing the B-glucan to centrifugation and purification by anion-exchange chromatography, e.g., on a
DEAE cellulose column, and eluting with water followed by 0.25 M NaCl; and (v) recovering the neutral fractions eluted with water and acidic fractions eluted with 0.25 M NaCl, subjecting them to size-exclusion chromatography, e.g., on a Sephadex G-50 column, to give purified B-glucan that is lyophilized (freeze- dried).
According to a further embodiment, the B-glucan is obtained from the submerged cultivated mycelial biomass of Ganoderma tsugae var. jannieae strain :
Tay-1 CBS 120394 by alkaline or acidic extraction as described for the fruiting bodies.
In another aspect, the present invention is directed to a composition comprising a B-glucan of the invention.
The composition comprising a f-glucan of the invention may be used as a nutriceutical composition alone or together with other nutrients, for example, agents having antioxidant activity such as carotenoids, flavonoids, tocopherols, ascorbates and mixtures thereof, and/or vitamins and minerals.
The compositions of the invention are preferably formulated in an oral solid dosage form such as, but not limited to, a fine powder, capsules, tablets, caplets, and sachets. These compositions may contain standard excipients and pharmaceutical acceptable carriers such as cellulose, methyl cellulose, carboxymethylcellulose and hydroxypropylmethylcellulose and lubricating agents. 17 i
The dosage of the composition to be taken by an individual will depend on ] his/her health condition. The dosage of B-glucan recommended for: healthy adults are 100 to 200 mg daily. In chronic conditions, the daily amount will be higher, usually double or more. In critical conditions, the amount is even higher and may reach from 1000 to 2000 mg, or even more, daily
The compositions of the invention may also be formulated into food and beverage products including bread, cereals, ice creams and fruit drinks. These health products can improve the health conditions of the individual and prevent or treat diseases and disorders as well documented for B-glucans and as described below. The beverage food product may be an energizing beverage product further containing other components such as vitamins, flavors, stabilizers and the like.
The composition comprising the f-glucan of the invention may be also formulated into a pet food products, e.g., dog and cat food products.
In one embodiment, the composition comprising the B-glucan of the invention may be formulated into a cosmetic product such as an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve or an ointment. . In another embodiment, the compositions of the invention, preferably in an oral solid dosage form or as a beverage product, are for use as dietary supplements.
In other embodiments of the invention, the compositions comprising the p- glucan of the invention are indicated for prevention or therapy of several diseases, disorders and conditions. : In one embodiment, the compositions comprising the B-glucan of the invention can be used for stimulation of the immune system and are thus useful as adjuvants to chemotherapy or radiotherapy of tumors in the treatment of cancer patients receiving such treatments. These compositions can also increase resistance to microbial agents and are also useful for prevention and treatment of infections, e.g., bacterial, parasitic or viral infections, including human immunodeficiency virus (HIV) infection. In the case of HIV infection, the B-glucan, in addition to immunostimulation of T-helper (Th)-2 cells, making them resistant to HIV infection, also seems to interfere directly with viral propagation.
In another embodiment, the compositions comprising the B-glucan of the invention can be used for in treatment of an NF-kB-dependent disease selected from cancer, immunological disorders, septic shock, transplant rejection, radiation damage, reperfusion injuries after ischemia, arteriosclerosis, osteoporosis, and neurodegenerative diseases. In one preferred embodiment, the composition is used in the treatment of a cancer such as breast, lung, bladder, colon, gastric tract, prostate or skin cancer, leukemia or lymphoma, either as sole treatment or together with antitumor drugs such as the monoclonal antibodies Herceptin, Rituxan and
Erbitux. .
The low molecular weight B-glucan of the invention administered as a composition or incorporated into food products is capable of lowering levels of total cholesterol and LDL (“bad”) cholesterol and of enhancing bile acid binding capacity ensuing improved hypocholesterolemic effects. These compositions and food products may thus be used for treatment of hypercholesterolemia and prevention and treatment of cardiovascular diseases and disorders such as arteriosclerosis and coronary artery diseases.
In another embodiment, the composition comprising the B-glucan of the invention is useful for controlling blood sugar levels and reducing glycemic index in Type II diabetes mellitus patients. oo
The invention will now be illustrated by the following non-limiting
Example 1. Characteristics of the variety Ganoderma tsugae var. jannieae
The variety Ganoderma tsugae var. jannieae has the following characteristics as described and depicted in Wasser et al., 2006: (i) Basidiomata: as depicted in Figs. 1-2. (ii) External habit. Basidiomata pedicellate orthopleuropodal (Figs. 1-2).
Pileus dimensions varying between 7-20 cm in diam, the thickness varying between 0.5 and 2 cm. Stipe about 1-2.5 cm in diam. The pileus covered by thin laccate crust, slightly radially wrinkled and regularly concentrically zonate, diamine brown. The pores 5-6 per 1 mm, of normal G. tsugae appearance. (iii) Section. Cutis 50-120 pm thick, hard and brittle. Context indistinctly two-layered. Upper layer wood-coloured to ochraceous buff, rather soft. Lower layer is ochraceous buff to coffee brown, penetrated by numerous laccate deposits, rather dense. Tubes one-layered, concolorous with the dense zone. (iv) Cutis. Hymeniderm, consisting of dense layer of pileocystidia 45-100 x 9-11 pm, amyloid (dark brown to almost black), broadly clavate to narrowly : clavate, narrowly utriform, thin-walled, few catenulate pileocystidia occur. (v) Hyphal system trimitic. Inflated skeletals not found. Generative hyphae 20-60(>) x 3-5 um, thin-walled, with short, small clamps not above every septae, slightly branched, seldom anastomozing; skeletal hyphae 40-120 x 3.0-7.5 pm, regularly branched, thick-walled, not regularly septated, clampless; binding hyphae 2.0-5.0 pm in diam, much branched, branches often tapering, thin- or thick-walled.
Apart from these types of hyphae lateral and modified skeletal hyphae were . observed. Lateral hyphae very thin, 1.6-2.0 um in diam, branching, seldom septate.
Arboriform skeletal ‘hyphae 50-80 x 3.2-5.0 pm, long thick-walled straight with abundant short thin dichotomically branching hyphae (reminding of a crown of a tree) at the apex and attenuate at the other end are present. All types of hyphae are inamyloid. (vi) Basidiospores. Spores pale-brown, (8.0)8.8-11.2 x 5.0-6.4 pm, average 9.6 x 6.4 um; inamylod; some spores with vacuoles; ovoid, oblong, germ pore noticeable, truncate or protruding; apiculus lateral, hardly discernable; spore wall two-layered, up to 2.0 pm thick, with rather wide, short, not crowded pillars between the two layers, endosporium rather thin. SSI (D x 100/L) = 50-80%, Co average — 66.7%. SI (L/D) = 1.2-2, average — 1.5. » (vii) Mycelial Characteristics
Thirty-day-old culture. Colony white, dense, downy (Fig. 3A), with faintly outlined concentric zones, some colonies develop well-discernable sectors.
Mycelium forming concentric zones and sectors is denser than the mycelium on the rest of the surface of a colony. The outline of the colony are even; mycelium at the margin is raised. Several types of hyphae are observed.
Vegetative mycelium of the center of the colony. Skeletal hyphae — 4.8-8.0 um in diam, thick-walled, cylindrical or slightly attenuate towards the septa, clampless, almost unbranched, not regularly septate. Generative hyphae 2.4-3.0 pmin diam, thin-walled, branched, regularly septate, with abundant short small clamps above almost every septa, some sections of generative hyphae are sclerified.
Binding hyphae thick or thin-walled, strongly branched, 3.24.0 pm in diam.Lateral hyphae 1.6 pm in diam, thin-walled, dichotomously branching.Furthermore, abundant staghorn hyphae are observed in the center of the colony .Vegetative mycelium of the growth zone. T hick-walled unbranched sceletal hyphae,and also generative and binding hyphae similar to those from the center of a colony are observed. Also, thin-walled 35-45 x 28-32 um cuticular cells and cystidia-like thin-walled utriform terminal cells are present. 24-40 x 18-16 um cells also occur.H-like anastomozes are abundant in all parts of the colony. Chlamydospores and aleuria not found. All types of hyphae and vegetative mycelial structures are inamyloid. :
Seventy-five-day-old culture. Colony white, dense, with concentric zones, reversum unchanged. Aerial mycelium very dense, cottony, felty in the center, subfelty with pronounced hyphal tufts near the edge of the Petri dish, interwoven, outline of margin even, mycelium at the margin is raised. 1
Vegetative mycelium of the center of the colony. The major types of hyphae (skeletal, generative, binding, and lateral) are observed. However, the number of clamps and staghorn hyphae greatly decreases; they are difficult to find. Chains of thin or thick-walled not branched hyphae 2.4-3.2 x (4.0)6-10(14) um and a lot of misshaped thick-walled vacuolarized cells 19.2-28.8 x 7.2-9.6 um occurred.
Vegetative mycelium of the growth zone. Same types of hyphae as in the one- month-old culture are observed. Moreover, staghorn hyphae appear and aged vacuolarized cells appear while the number of culticular cells decreases (Fig. 3B).
According to the present invention, from the variety Ganoderma tsugae var.
Jannieae a new strain was isolated and characterized and was deposited under The
Budapest Treaty with the Centralbureau voor Schimmelcultures (CBS) under
Accession No. CBS 120394.
Example 2. Submerged cultivation of mycelial biomass of Ganoderma tsugae var. jannieae strain Tay-1 in Erlenmeyer flasks and fermentor
Fig. 4 shows the general methodology for the production of submerged cultured mycelium of Ganoderma tsugae var. jannieae using fermentor or bioreactor technology.
The general scheme of mushroom submerged culture mycelium (SCM) production includes 5 steps of culture growth:
Museum culture (I) —> Intermediate culture (II) —> Pre-inoculums culture (III) —> Inoculums culture (IV) —> Fermentation culture (V).
Three types of culture media are used for SCM production: standard agar medium (steps I and II), liquid standard inoculums medium (steps III and IV), and fermentation medium (step V). Museum cultures are developed on agar slants in tubes; intermediate cultures are developed on agar slants in tubes or Petri dishes.
Pre-inoculums and inoculums cultures are developed in Erlenmeyer flasks using a rotary shaker. Fermentation cultures are developed in fermentor Bioflo 2000 (New
Brunswick Scientific, USA) that is equipped with instrumentation for the measurement and/or control of agitation, temperature, pH, dissolved oxygen concentration (p0O,), and foam.
For the first pre-inoculums culture, a 250 mL Erlenmeyer flask is inoculated by one to three week old mushroom mycelium from the Petri dish. Five-to-six pieces
(5-7 mm in diameter) from mycelium growing on the edge of the agar plate were transferred into the Erlenmeyer flask and cut on the flask wall into small pieces to increase the number of growth points of mycelia. Mycelium was inoculated in 250- mL Erlenmeyer flasks filled with 100 ml of defined synthetic medium. Fungal inocula were grown on synthetic medium consisting of the following components (g/L of distilled water): glucose, 25.0; peptone, 3.0; KH,PO,, 1.0; K,HPO,, 0.2;
MgSO, 7H,0, 0.5; yeast extract, 3.0. Phosphate salts were sterilized separately (Sigma-Aldrich, St Louis, MO, USA). The cultivation of inoculated flasks is carried out on a rotary shaker at 160 rpm and 27°C for 6-7 days. At the end of cultivation (Figs. 5-6), 1 mL of sample is taken from the culture for microscopicobservation of culture purity.For the second inoculumss culture the biomass from the first pre-inoculumsculture (pellets) was homogenized (Fig. 7) 2 x 30 seconds using a Waring
Laboratory Blender (Waring, USA) and inoculated in a 2 L flask containing 700mL of the same medium.After 5-7 days of cultivation, mycelial biomass (pellets) (Fig. 8) were homogenized and used as inoculums culture for growth in a fermentor (Bioflo 200010 L, New Brunswick Scientific, USA) with 10 L of working volume on the same synthetic medium mentioned above. Initial parameters of cultivation were as follows: temperature 27°C; pH — 6.1; agitation — 100 rpm, aeration — 0.2 v/v/min.
Antifoam used was polypropylene glycol 2000; 4% NaOH and 4% HC! were used to control pH.Initially, pH of the medium was not controlled. However, when it decreased to 5.2, the pH was kept constant automatically at the level of 6.0 to favor the fungus growth. After 24 h, the speed of agitation was increased to 200 rpm, then after 48 h to 300 rpm. After 48 h, the rate of aeration of the medium was increased to 0.4, then (after 72 h) to 0.5 v/v/min.
The maximal yield of mycelial biomass was 113 g/L of wet biomass (Fig. 9) or 11.3 g of dry biomass (Fig. 10) achieved on day 7 of fungus cultivation. The conditions of the cultivation are defined in Table 1. Vacuolated hyphae with clamp connections of mycelial biomass of Ganoderma tsugae var. jannieae CBS 120394 after 7 days of fungus cultivation are depicted in Fig. 11.
Table 1. Mycelial biomass production of Ganoderma tsugae var.
Jannieae strain Tay-1 in submerged culture as a function of time 100-200 08 58-60] 19 | 02-04 72 | 60 | 17 | 04-05 | 300 | 60 9% | 60 | 14 | 05 | 300 | 79
DO, dissolved oxygen
Example 3. Isolation of B-glucan from dried fruiting bodies biomass of
Ganoderma tsugae var. jannieae strain Tay-1
Polysaccharides were isolated from Ganoderma tsugae var. jannieae strain
Tay-1 using alkaline or acidic extraction. Dominant $-glucan was most efficiently isolated by boiling diluted sulfuric acid at pH 1.5. Using alkaline extraction, B- glucan, galactan and mannan were isolated, with the two latter products in minor quantity. The B-glucan was characterized by chemical analysis, methylation, acetolysis, and NMR spectroscopy. It was found to have an irregular branched structure with the main chain consisting of p-1-3- and B-1-4-linked glucopyranose residues with side chains consisting of B-1-6-glucopyranose oligomers, attached to
O-6 of some monosaccharides of the main chain. :
Materials and Methods 3.1 General Methods 'H and >C NMR spectra were recorded using a Varian
Inova 500 spectrometer (Varian, USA) in D,0 solutions at 40 °C for the polysaccharide with acetone standard (2.225 ppm for 'H and 31.5 ppm for °C) ! using standard pulse sequences COSY (homonuclear correlation spectroscopy),
TOCSY (total correlation spectroscopy; mixing time 120 ms) and NOESY (nuclear
Overhauser effect spectroscopy; mixing time 200 ms), HSQC (heteronuclear single quantum correlation), and HMBC (multiple-bond C-H correlation; optimized for a
Hz coupling constant).
For monosaccharide analysis, the polysaccharide (0.5 mg) was hydrolyzed (0.2 mL of 3 M trifluoracetic acid (TFA), 100 °C, 2 h), followed by evaporation to : dryness under a stream of air. The residue was dissolved in water (0.5 mL), reduced with NaBH; (~5 mg, 1 h), neutralized with acetic acid (0.3 mL), dried, and methanol (1 mL) was added. The mixture was dried twice with the addition of i MeOH, and the residue was acetylated with acetic anhydride (Ac,0) (0.5 mL, 100 °C, 30 min), dried and analyzed by Gas Liquid Chromatography (GLC) on an HP1 capillary column (30 m x 0.25 mm) with a flame ionization detector (Agilent 6350 chromatograph (Agilent, USA) in a temperature gradient of 170 (4 min) to 260 °C at 4 °C/min. + For protein determination 2,2"bicinchoninate assay kit from Pierce
Biotechnology (USA) was used according to the supplier's instructions.
Gel chromatography was carried out on Sephadex G-50 (2.5 m x 95 cm), column (GE Healthcare) using the pyridinium acetate buffer, pH 4.5 (4 mL pyridine and 10 mL AcOH in 1 L water) as the eluent, monitored by a refractive index detector.
Anion-exchange chromatography was performed on a column of DEAE cellulose (15x5 cm), washed with 1 M NaCl and then water. The sample was applied in water, and eluted with water (500 ml), 0.25 M NaCl (500 ml), and then 1
M NaCl for regeneration. 0.25 M NaCl extract was desalted by dialysis. 3.2 Methylation analysis The sample of the polysaccharide (2-3 mg) was dissolved in Me,SO (1.0 mL), powdered NaOH was added (~50 mg), the mixture was stirred for 30 min, 0.5 ml of Mel was added, then the mixture stirred for 30 min, excess Mel was removed by air stream, water was added (5 ml), methylated polysaccharide was extracted with chloroform, extract washed with water 3 times, and dried. It was then hydrolyzed (3M TFA, 100 °C, 1 h), reduced (NaBD,),
: acetylated, and analyzed by a Varian Saturn 2000 ion-trap GS-MS instrument (Varian, USA). 3.3 Acetolysis. Glucan (80 mg) was dissolved in water (1 ml), diluted with pyridine (10 mL), and acetic anhydride was added (10 mL). The homogeneous mixture was kept 30 min. at 100°, and then evaporated to dryness. Acetylated glucan was dissolved in acetic acid (10 mL), cooled on ice, and Ac,0 (10 mL) and
H,S0, (0.5 mL) were added. The mixture was kept three days at room temperature, poured in cold water, after one hour it was extracted with chloroform 3 times.
Unexpectedly, organic extract contained only a-glucose pentaacetate; acetylated oligo/polysaccharides were not extracted by chloroform. To extract them, NaCl was dissolved in the aqueous layer to saturation, and products were extracted with chloroform, to give acetylated polysaccharide. It was deacetylated with 0.1 M
MeONa in MeOH and analyzed by NMR and methylation (after borohydride reduction to prevent peeling). The hydrolysis of glycosides and polysaccharides to reducing sugars and the concomitant conversion to alditol acetates (borohydride reduction and acetylation) is a standard method to analyse polysaccharides containing aldoses, ketoses, deoxyaldoses, and acetamidohexoses and other related sugars. 3.4 Isolation of B-glucan is carried out by different procedures. The alkaline extraction is schematically depicted in Fig. 12.
Powdered dry fruiting bodies biomass of Ganoderma tsugae var. jannieae (1 kg) were washed with boiling 85% EtOH (5 L, 3h, repeated 3 times) and ethanol extract was discarded.
The remainder was extracted with boiling water (5 L, 100°, 3 h, 5 times), the solution was dialyzed, concentrated by evaporation on the rotary evaporator to ~1
L. This solution was shaken with 200 mL of chloroform-isoamyl alcohol (10:1) for min, centrifuged at 10000 rpm for phase separation, water-layer treated in the same way one more time, and freeze-dried to give crude B-glucan that purified by anion-exchange chromatography, yielded 1.5 g (0.15%) of B-glucan. 26
BN
Half of the insoluble residue from water extraction was boiled with 5%
NaOH - 0.05% NaBH, (5 L, overnight, repeated twice). Extract was neutralized with concentrated HCI to a pH of 4, at which point the maximum of the precipitate was formed. Precipitate was removed by centrifugation (10000 rpm, 30 min).
Solution was dialyzed against running water, concentrated to 1 L volume, solution was lyophilized, yielding 28 gram (2.8 %). It was dissolved in water (200 mL), centrifuged at 40,000 rpm, and the B-glucan was purified from solution by anion- exchange chromatography. B-glucan was found in water and 0.25 M NaCl eluates.
Both neutral and acidic fractions were separated by size-exclusion chromatography on Sephadex G-50 column (2.5x80 cm) to give 3 g (0.6%) of B-glucan, as well as 500 mg of a mixture containing B-glucan, galactan, and mannan.
A quarter of the insoluble residue from water extraction was boiled in 0.01
M H,80, (5 L, 4h, repeated twice). Extracts were dialyzed and further treated in the same way as alkaline extract, yielding 5 g (2%). 3.5 Results Standard determination of monosaccharide content of the whole mushroom using complete acid hydrolysis and gas chromatography of alditol acetates showed glucose and glucosamine in the respective amount of 6 and 3% by weight. Other monosaccharides were identified in small amounts.
Sawmill dust-like powder prepared by destruction of the dry mushrooms using a high-speed blender was defatted by boiling in three portions of 85% ethanol, and then extracted three times with boiling water. Extract was dialyzed, deproteinized using Sevag protocol (Sevag et al., 1938), concentrated, clarified by ultracentrifugation at 40,000 rpm, and freeze-dried. Monosaccharide analysis (GC of alditol acetates) showed the presence of 56% glucose, 4% galactose, 5% mannose, 1.5% fucose, and 1% xylose. Bicinchoninic acid (BCA) estimation of the protein content showed 32% of protein (possibly overestimated). Anion-exchange and size-exclusion chromatography of the freeze-dried product (dissolved in water) yielded 1.5 g of B-glucan.
] The portion of the solid remainder of water extraction was treated essentially as described by Mizuno et al. (1995) with some modifications (particularly, temperature of extraction was increased as it leads to better yield): it was boiled in 5% NaOH-0.05% NaBH,, filtered, solution neutralized by conc. HCI to pH 4.
Massive precipitation occurred; the precipitate was removed by centrifugation. The precipitate was insoluble in water but could be dissolved in alkaline conditions. It gave no signals in NMR spectra. Quantitative monosaccharide analysis showed the presence of a small amount of glucose (it was not analyzed further).
The neutralized solution was dialyzed, concentrated by roto-evaporation, deproteinized using Sevag protocol (Sevag et al, 1938), clarified by ultracentrifugation at 40,000 rpm, and freeze-dried. The product had a dark brown color. Widely used ethanol precipitation was attempted for polysaccharidepurification, but it did not give good results: NMR of the EtOH precipitate andsolution showed that B-glucan was distributed between both fractions, apparently higher molecular mass glucan dominated in the precipitate, and shorter chains remained in solution. Other polysaccharides were found mostly in the precipitate.
Ethanol precipitation was not used for large-scale polysaccharide isolation.The product was further separated by anion-exchange chromatography on
DEAE-cellulose. Most of the brown color was adsorbed on the column packing.
Two fractions of glucan were isolated: neutral (eluted with water) and acidic i (retained in water and eluted with 0.25 M NaCl). It seems that retention of B-glucanis due to the presence of unidentified acidic group(s), present in very low amounts per one polysaccharide chain. Therefore, glucan was weakly retained on a DEAE sorbent. Each fraction, retained and non-retained, on re-chromatography gave twofractions again, retained and non-retained. Thus retention of the glucan is non- specific, and both products are identical. They had identical NMR spectra (not shown) and contained ~5% of protein. Overall yield of B-glucan from NaOH extraction was 0.6%.
A portion of the remainder after ethanol and water extraction was treated using the procedure described by Yap and Ng (2001). It was frozen in liquid
- nitrogen, lyophilized, and extracted again with boiling water. Although there is no description in the original article, it could be assumed that freezing destroys cell walls and thus facilitates extraction of the polysaccharides. However, nothing was extracted in this way, except some proteins.
A portion of the remainder after ethanol and water extraction was extracted using the method described for B-1,3-glucan isolation (Storseth et al., 2005): the material was boiled in 0.01 M H,SO, (pH 1.5), filtered, dialyzed, deproteinized using Sevag protocol (Sevag et al, 1938), concentrated, clarified by ultracentrifugation at 40,000 rpm, and freeze-dried. The product had light brownish color. NMR showed that some protein and/or lipid impurities were still present.
The product was mainly B-glucan; the yield was 2%. B-glucan was further purified by anion-exchange chromatography as described above. 3.6 Separation of the B-glucan from other polysaccharides. Size-exclusion chromatography of the mixture of polysaccharides showed a broad molecular mass distribution covering the whole separation range of Sephadex G-50 (500-10000
Da). Three polysaccharides were detected in the mixture — glucan (Glc), galactan (Gal), and mannan (Man). The maximum of molecular weight of the glucan was about 5000 Da. The other two polymers had distinctly higher molecular masses and were eluted close to the void volume of the column. They were not obtained in an individual state, but only as a mixture with two other polysaccharides (not shown). "H-NMR spectra of the fraction containing the purified glucan, as depicted in Fig. 13, and of the fraction of the void volume containing mannan, galactan, and glucan (Fig. 14), show the different compounds present in the two fractions. 3.7 Analysis of the structure of p-glucan.
Monosaccharide analysis of the isolated B-glucan showed the presence of glucose (~90%). Measured protein content (bicinchoninate method) was ~5%.
Methylation analysis of the glucan showed the presence of terminal, 3-, 4-, 6-, 4,6-
and 3,6-substituted glucose residues in the ratio of 1:0.64:1.04:0.52:0.12:0.52 (Fig. 15).
Table 2 shows the NMR data for the B-glucan (ppm; D,0, 40°C). Signals of 4,6-disubstituted glucose were not identified.
Table 2. Chemical shifts of "H and C of glucose
H/C-2 H/C-6 4.52 or 4.76 3.72/3.91 lc [1042 4.52 or 4.76 3.86/4.20
Cc 1042 4.52 or 4.76 3.72/3.91 [c [1042 4.52 or 4.76 3.80/3.97
C [1042 -3,6-Gle 4.52 or 4.76 3.86/4.20
Lc [1042 [745 |859 [696 [764 [704
Interpretation of the 2D NMR spectra of the glucan in Table 2 showed the : presence of variably linked B-glucose residues. No clearly defined repeating units were observed. Because of irregular structure, interpretation of 'H 2D correlation spectra was difficult; assignment of the proton signals — but no sequence information — could be deduced. Substitution types of the monosaccharides were deduced from HMBC spectra (Fig. 15) (Duus et al., 2000)
The signals of all B-glucopyranosides with the substitution types determined by methylation were observed (with the exception of low abundant 4,6- disubstituted glucose residues). It was impossible to determine the arrangement of differently substituted residues in the main chain.
The lengths of the side chains were determined using acetolysis, which is known to break only 1-6-linkages. Treatment of the acetylated glucan with Ac,O-
H,S04 led to isolation of a-glucose tetraacetate, identified by NMR, and of the acetylated main chain of the glucan. This result can be interpreted as a confirmation of the presence of oligomers of 1-6-linked B-glucose in the side chains, whereas the ;
main chain contained no 1-6-linkages. The number of 6-substituted glucose residues is half of the number of terminal ones according to the methylation data, thus the side chains are composed of single glucose units and B-Glc-(1-6)--Glc disaccharide.
The data obtained could be interpreted as belonging to the following structure:
A B
Cc D B-D-Glcp-(1-{-6)-B-D-Glep-(1-o.r] -[-3)-B-D-Glep-(1-]ion-[-4)-B-D-Glep-(1-]6n-[-3)-B-D-Glep-(1-]sn-[-4)-B-D-Glep-(1-1a-
B-D-Glcp-(1-[-6)-B-D-Glop-(1-Jo.- B F
A B where n is an integer number > 1.
The different components represented by capital letters in the representation of the B-glucan structure are as follows:
A- B-D-Glcp-(1-6)
B- B-D-Glep-(1-]0-1
C- -[-3)-B-D-Glcp-(1-]10n
D- -[-4)-B-D-Glcp-(1-]6n
E- -[-3)-p-D-Glep-(1-]5n
F- -[-4)-B-D-Glcp-(1-]n
The B-glucan is characterized by high solubility in water giving a clear aqueous solution, which becomes brown at high concentrations. The lyophilized dry B-glucan is an odorless white powder.
The signals of all B-glucopyranosides with the substitution types determined by methylation were observed. It was impossible to determine the arrangement of differently substituted residues in the main chain.
The lengths of the side chains were determined using acetolysis. Acetolysis is known to break only 1-6-linkages. Treatment of the acetylated glucan with
Ac,0-H,S0, led to isolation of a-glucose tetraacetate, identified by NMR, and of 31
Cd the acetylated main chain of the glucan. This result can be interpreted as a confirmation of the presence of oligomers of 1-6-linked B-glucose in the side chains. : :
Various preparations of p-glucan contained different amounts of impurities.
Presented spectra contain sharp signals of o-1-3-mannan (marked with stars in Fig. 16). Other samples (not shown) contain no such signals; thus mannan is not chemically linked to the glucan structure.
MALDI (Matrix Assisted Laser Desorption Ionization) mass spectra of glucan showed broad mass distribution. Peaks starting from m/z 510 up to 5,000 were observed (Fig. 17). This does not reflect real mass distribution, since signal intensity decreases with molecular mass due to lower volatility of the heavy components. Since the spectrum corresponds to molar mass distribution, it also overestimates low-molecular mass components. The spectra showed no variations in peak-to-peak distances, which corresponded to hexose residues (162 amu; peaks are sodium and potassium adducts). Thus, the glucan contained no additional substituents along the chain. However, the overall mass could not be explained as belonging to a polymer built of glucose only. The nearest peaks to that calculated for a molecule containing only hexoses are 16 amu lighter. Thus, the glucan probably has some non-glucose residue at the reducing or non-reducing end.
Attempts to determine its nature by NMR and chemical analysis failed.
In summary, B-glucan is present in dried fruiting bodies of Ganoderma tsugae var. jannieae in an amount not exceeding 6%, total glucose-is 6% of the dry weight. It seems that B-glucan is not chemically bound to the other mushroom components, since it can be extracted in neutral, acidic, or basic conditions. The best yield of B-glucan was obtained by acidic extraction. Repeated extractions give additional smaller amounts of B-glucan.
B-glucan has an irregularly branched structure with the main chain consisting of B-1-3- and B-1-4-linked glucopyranose residues with side chains :
consisting of short B-1-6-glucopyranose oligomers attached to 0-6 of the ] : monosaccharides (mostly 3-substituted) of the main chain.
Molecular mass of the isolated B-glucan is below 10000 Da with broad molecular mass distribution, centered at about S000 Da.
The glucan contains no additional components except glucose, but seems to have a different reducing end residue. The reason for its retention on anion- exchange column remains unknown.
Two other polysaccharides, mannan and galactan, are co-extracted with the glucan. These polysaccharides are present in low concentration in the mushrooms, but are more easily extracted than B-glucan.
As described in the Background section, B-glucans from fungi possess many biological activities and are beneficial in the prevention and treatment of several human health conditions. The low-molecular mass of Ganoderma tsugae var.
Jannieae B-glucan may give it an advantage in possibly better internalization using oral administration. Its structure is unique.
Example 4. Isolation and characterization of P-glucan from submerged cultivated mycelium of CBS 120394 Ganoderma tsugae var. jannieae strain
Tay-1
Polysaccharides were isolated from submerged cultured mycelium of
Ganoderma tsugae var. jannieae strain Tay-1 using water, NaOH or H,SO, extraction. Dominant B-glucan was most efficiently isolated by boiling the mycelium in diluted sulfuric acid at a pH of 1.5. B-glucan and other polysaccharides were characterized by chemical analysis, methylation, and NMR spectroscopy. The B-glucan from submerged cultured mycelium had an irregular branched structure similar to the p-glucan isolated from fruiting bodies, with the main chain consisting of B-1-3- and B-1-4-linked glucopyranose residues with side chains consisting of B-1-6-glucopyranose oligomers, attached to 0-6 of some monosaccharides of the main chain.
One can expect that the Ganoderma tsugae var. jannieae glucan have high : biological activity because it combines structural elements of several active polysaccharides: it has alternating f-1,3;1,4-linkages in the main chain as in the glucan from plant cell wall, and branches at O-6 like fungal glucan or lentinan. It also has low molecular weight, which is beneficial for bioavailability.
Results Monosaccharide analysis (acid hydrolysis and gas chromatography of alditol acetates) of the cells of the fruiting bodies and mycelium of Ganoderma tsugae var. jannieae strain Tay-1 was performed in different hydrolysis conditions: (1) Conc. HCI - 37% HCI, 100°, 15 min., then solution was diluted 1:1 with water and hydrolysis continued for 1 h at 100°; (2) 2M HCI - 100° 4 h; 3M TFA - 120°, 4 h; (3) HF-TFA - anhydrous HF 25°, 1 h, then 3M TFA, 120°, 4 h). The results are shown in Table 3 below, in which percents are calculated from GC peak integration area relative to internal inositol standard.
The results in Table 3 demonstrate significant differences in monosaccharide content in the different hydrolysis conditions; glucose (Glc) content varied from 5% to 10%, and glucosamine (GlcN) content varied from 0.5 to 5%. This can be explained by different solubility of the samples in different acids.
The highest determined quantity of the monosaccharides still does not reflect the real concentration of the monosaccharides, which can be even higher.
The overall glucose content is lower in the mycelium comparing to dried fruiting bodies biomass of Ganoderma tsugae var. jannieae strain Tay-1 mushroom, and glucosamine is higher. The results for galactose are unusual in that its concentration in fruiting bodies is very low, or it seems to be absent, whereas the mushrooms contain significant amounts of easily extractable galactan.
Table 3 . Relative amount (%) of monosaccharide of the fruiting bodies and 3 submerged cultivated mycelial biomass of Ganoderma tsugae var. jannieae strain
Tay-1 in different hydrolysis conditions.
[Source [Conditions [Xyl [Man [Glc [Gal |GleN aMHCL | Joo [18 Jo Jo2 2MHCL | [15 [75 [07 |08
Fruitingbodies [SMTFA | [12 [137 [0 [0
Mycelium |3MTFA [12 [12 [5 [08 [05
Fruitingbodies |HF-TFA | [05 [S50 [0 [32 [Mycelium |HF-TFA ~~ [ [14 [10 Jo5 [12
Xyl, xylose; Man, mannose; Glc, glucose; Gal, galactose; GlcN, glucosamine 4.1 Isolation of polysaccharides. All experiments were as described for the fruiting bodies of Ganoderma tsugae var. jannieae (Example 2). For isolation of ; polysaccharides, mycelium of Ganoderma tsugae var. jannieae strain Tay-1 was washed by boiling 85% ethanol 3 times and then extracted with boiling water for 8 h. The insoluble material was then boiled in diluted H,SO, (~0.01 M, pH adjusted to 1.5) for 8 h, or in 5% NaOH for 12 h. The products were dialyzed and dried. All extractions gave a product containing protein, B-glucan, galactan and other contaminants. The yield of acid extraction was comparable to the yield of alkaline : extraction. At the end of all these treatments, the dry insoluble residue of the cells was 30% of the original weight of the starting material. The monosaccharide composition was close to that of the untreated cells, which indicates the presence of tightly bound polysaccharides, probably residing inside the cells.
NaOH extract was cleared by acid precipitation and the precipitate was discarded. All products were then separated by anion-exchange chromatography, which gave a neutral fraction, composed mostly of galactan and mannan with some glucan and other impurities and an acidic fraction of the purified B-glucan. Finally, polysaccharides were purified by size-exclusion chromatography. Overall yield of
B-glucan was 3%. The glucan had low molecular weight of <5000 Da, similar to that of the glucan isolated from the fruiting bodies. Some of the glucan was probably lost during dialysis.
4.2 Analysis of the structure of p-glucan from submerged cultivated mycelial : biomass of Ganoderma tsugae var. jannieae strain Tay-1. Monosaccharide analysis of the isolated B-glucan from mycelium of Ganoderma tsugae var.
Jjannieae strain Tay-1 showed the presence of glucose (~90%). Measured protein “content (by the bicinchoninate method) was ~5%. Methylation analysis of the glucan showed the presence of terminal, 3-, 4-, 6-, 3,6- and 4,6-substituted glucose residues in the ratio of 1:0.75:0.25:1.6:0.1:0.6. The amount of 4-substituted glucose was significantly lower - and the content of 6- and 3,6-substituted glucose was higher - in the glucan extracted from mycelium compared with the glucan extracted from the fruiting bodies (Fig. 18).
As with the fruiting bodies in Example 2, two other polysaccharides, galactan amd mannan, were co-extracted with the p-glucan. The galactan from the mycelium had the same structure as galactan extracted from fruiting bodies with o- 1-6-linked galactopyranose in the main chain and with a-fucose branches at O-2. - NMR spectra of the glucan from submerged cultivated mycelial biomass was similar to the spectra of the glucan from dried fruiting bodies (Fig. 19).
Thus, one can conclude that B-glucan from mycelium and from fruiting bodies of Ganoderma tsugae var. jannieae strain Tay-1 has the same overall structure with some quantitative differences, e.g., lower content of 4- and 4,6- substituted glucose and longer side chains of B-1-6-linked glucose. Molecular mass of the isolated p-glucan is below 10000 Da with broad molecular mass distribution centered at ~5000 Da. The glucan contains no additional components except glucose, but seems to have different reducing end residue.
Example 5. Ganoderma tsugae var. jannieae strain Tay-1 extract as a potential ! modulator of the NF-kB activation pathway
It is widely accepted in the scientific community that the active component in mushroom extract that have immuno-stimulatory and anti-cancer activity is comprised largely of fB-glucans (Lull et al., 2005, Luhm et al., 2006; Chen and
Seviour, 2007). The molecular mechanism by which the B-glucans exert their activity often involves the NF-xf pathway as already mentioned above (e.g.
Kataoka et al., 2002). The activity of the mushroom extract was tested in vitro in a human breast cancer cell line.
Material and methods 5.1 Mushroom cultivation and biomass extraction. A pure mycelial culture of
Ganoderma tsugae var. jannieae strain Tay-1 was obtained after being maintained on Suslo-Yeast extract-Agar (SYA) (Conda Laboratories, Spain) medium composed of: 0.5 liter Suslo (an aqueous malt extract boiled with hops), 0.5 liter distilled H,O, 0.5 g peptone, 0.5 g yeast extract, 17 g agar-agar, 0.5 g MgSO, (anhydrous), and 1 g streptomycin; pH — 5.5. Five mycelial disks, with a diameter of 5 mm, were inoculated in 250 mL flasks with 100 ml Yeast Extract (YE) medium containing (g/liter): glucose, 10; yeast extract (Conda Laboratories, Spain), 3; peptone, 2, KH,PO,, 0.8; Na,HPO,, 0.2 and MgS0,.7H,0, 0.25. The inoculums were incubated on a rotary shaker at room temperature. When the grown mycelium filled out the culture medium, the whole flask content was homogenized, divided into 2-liter flasks (containing 1 I. YE medium), and put on a rotary shaker (Orbital
Shaker Incubator, M.R.C., Ltd., Israel) for 10 days at 27°C and 140 rpm for biomass production. The obtained biomass was washed twice with 1 L of distilled water, dried, ground into a fine powder, and divided into 3 equal portions, each one of which was extracted three times per 30 min with one of the following organic solvents (Frutarom, Israel): ethyl alcohol (EAL), ethyl acetate (EAC), and diethyl ether (DEE) in the ratio of 1 g: 10 mL. Culture liquid (CL) was also extracted with ethyl acetate in the ratio of 1 L (CL): 500 ml ethyl acetate. The total of four crude organic extracts were obtained and named as follows: W01 (mycelial DEE extract);
WO02 (mycelial EAC extract); W03 (mycelial EAL extract); and W04 (CL extract).
All the extracts were diluted with 99.9% DMSO (dimethyl sulfoxide) (Sigma-
Aldrich, St Louis, MO, USA) to a final concentration of 50 mg/mL and kept at - 70°C. 5.2 Cell culture. The human breast cancer cell line MCF7 (ATCC, Rockville, MD,
USA) was transfected with a NF-kB responsive reporter plasmid, NF-xB-LUC (Clontech, USA), connected to a luciferase responsive gene. Transfected cells were maintained in RPMI 1640 medium with L-glutamine, supplemented with 10% fetal calf serum (FCS) and 1% PenStrep (penicillin + streptomycin), and G418 antibiotic \ (Sigma-Aldrich, St Louis, MO, USA), in the concentration of 1 mg/mL. Baf3/p185
Ber-Abl (B-lymphocytes, a laboratory model of chronic myelogenous leukemia (CML), 9L (rat glioblastoma), and PC3 and DU145 (human androgen-independent prostate cancer) cell lines, obtained from ATCC (Rockville, MD, USA), were also maintained in RPMI 1640 medium with L-glutamine, supplemented with 10% FCS and 1% PenStrep. Cells were grown in a humidified incubator at 37°C with 5%
CO, in air and fed twice a week with fresh medium. 5.3 Luciferase reporter gene assay. MCF7 transfected cells (4x10%) were seeded in 200 pl of medium, using 96-well plates. After 24 h, mushroom extracts were added in several concentrations: 10, 25, 50, and 100 pg/ml. Control wells were: solvent- treated wells (1% of DMSO); parthenolide, an inhibitor of IxBa phosphorylation (Sigma-Aldrich, St Louis, MO, USA); and MGI132, an inhibitor of IxBa degradation (Calbiochem, San Diego, CA, USA). After 24 h, luciferase levels were determined according to the manufacturer’s instructions using a microplate luminometer (Anthos Labtec Instruments, Wals, Austria). The extracts’ reporter inhibition was expressed as percent relative to DMSO treated cells. 5.4 Cytotoxicity assay. To evaluate the effect of Ganoderma tsugae var. jannieae strain Tay-1 extracts on cell viability, the trypan blue exclusion method was applied. Cells (2x10°) were treated with the crude organic extracts in the concentrations of 125, 25, and 5 pg/mL. After 24 h, cells were collected, stained
: with 0.4% trypan blue solution (1:1), and counted using a hemacytometer. Solvent- treated samples were used as a negative control. 5.5 Sodium dodecyl sulphate-polyacrylamide electrophoresis (SDS-PAGE) and
Western blot analysis. Transfected MCF7 cells (2x10°) were seeded and then starved overnight with 0.5% FCS-containing medium. Twenty-four hours later, cells were supplemented with TNF-a (10 ng/mL) for 10 min in the presence of appropriate concentrations of the crude mushroom extracts. A solvent-treated sample was used as a negative control, and positive controls included samples treated with 10 pM of parthenolide or MG132, respectively. Cells were harvested, washed 3 times with cold PBS, and lysed with 50 pl of cell lysis buffer/1x10° cells (Sigma-Aldrich, St Louis, MO, USA), supplemented with 0.33% of PMSF (phenylmethylsulfonyl fluoride), and 1% of both protease and phosphatase inhibitor cocktails (Sigma-Aldrich, St Louis, MO, USA). Protein concentrations of the samples were determined using Bio-Rad DC protein assay (Bio-Rad, Hercules, CA,
USA). Equal amounts of proteins (30 pg) were separated using 12% SDS-PAGE, ~ transferred to a nitrocellulose membrane (Schleicher & Schuell BioScience GmbH,
Dassel, Germany) and subjected to Western analysis. Anti-IkBo or anti-pIkBa antibodies were used following the manufacturer’s instructions (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Target proteins were visualized by an
ECL detection kit (Amsterdam, The Netherlands) according to the manufacturer’s instructions. The equality of sample loading in each line was confirmed by stripping and reblotting with anti-beta-tubulin antibody (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA); however, a portion of blots (mainly for plxBa) was confirmed by Coomassie Brilliant Blue gel staining or by Ponceau Red membrane staining following the blotting. 5.6 Cell line sensitivity to parthenolide. A variety of cancer cell lines including
MCEF7 (breast cancer), Baf3/p185 Bcr-Abl (B-lymphocytes, a laboratory model of
CML), 9L (rat glioblastoma), and DU145 and PC3 (human androgen-independent prostate cancer) were used. Cells (2x10°) were seeded in 2 ml of medium and maintained for 24 h as previously described. Drugs were then added as follows: 1% ’ DMSO; parthenolide, in the concentrations of 20, 10, 5, and 1 uM; and Ganoderma tsugae var. jannieae extracts, in the concentrations of 250, 125, 50, 25, and 5 pg/ml. Imatinib (Gleevec®, a drug for treatment of CML; Novartis, Switzerland)), in 10 pM and 1 pM, was used as a positive control for the CML cell line. Cell viability was measured at 48 h post-treatment using the trypan blue exclusion method. 5.7 Statistical analysis. Results from the duplicated luciferase reporter gene assay are presented as an average fold of each extract treatment versus the DMSO values.
Data received from the cytotoxicity assay were calculated as sample values versus the solvent-treated value, which was used as a negative control. The analyses of the
Western blots for IxBa and plkBa levels in response to the mushroom extracts’ effects are presented as folds to only TNF-a treatment for 5 min (for pIlkBa) or 10 min (for IxBa), respectively. :
Results 5.8 Ganoderma tsugae var. jannieae strain Tay-1 extracts inhibit NF-kB- mediated reporter activity. The duplicate luciferase-reporter gene assay resulted in two (out of the four tested) Ganoderma tsugae var. jannieae strain Tay-1 extracts, which demonstrated reporter inhibitory activity by more than 40%. These were the WO1 (DEE extract) and W02 (EAC extract), both of which were active only in the higher concentration used, 100 pg/mL (Fig. 20). However, among them, the WO02 extract showed higher potential, inhibiting the reporter (luciferase) activity by more than 70%, and was therefore selected for further evaluation. 5.9 Effect of W02 Ganoderma tsugae var. jannieae strain Tay-1 extract on cell viability. The effect of the W02 extract (EAC extract) on cancer cell viability was evaluated by using three different concentrations, 125, 25, and 5 pg/mL. As shown in Fig. 21, the WO2 extract, in all tested concentrations, was not toxic for the cells and exerted a growth inhibitory effect lower than 30%. Considering the high reporter inhibition (of more than 70%) and the low cytotoxicity (less than 30%) of
WO02, it was assumed that the extract’s activity is due not to the direct killing of the cancer cells but to the interference in the intracellular surviving mechanisms, which interact with the NF-xB pathway. 5.10 Effect of W02 Ganoderma tsugae var. jannieae strain Tay-1 extract on
IxBa and p-IxBa levels. [kBa is a negative regulator of the NF-kB pathway and its levels are regulated by its degradation in the proteasomes. TNF-a. is known to be the classical activator of the NF-kB proapoptotic pathway. Therefore, in the present experiment, it was used as a control treatment, according to which the activity of
W02 mushroom extract could be estimated.
Our preliminary data have established the kinetics of changes in IkBa and phospho-IkBa (plkBo)levels in response to TNF-o-stimulation. Results showed that TNF-a treatment (10 ng/mL) for 10 min caused the highest level of IkBa degradation, and the treatment with 10 uM of MG132 caused inhibition of IkBa degradation. Also, a 5 min treatment with TNF-a caused the highest level of IkBa phosphorylation, and the treatment with 10 uM of parthenolide significantly inhibited IxBo. phosphorylation. Therefore, in order to check the effect of W02 on
IkBa degradation, it was applied as a 10 min treatment, and for checking its effect on IkBo phosphorylation, it was applied as a 5 min treatment to the cells. The results, as depicted in Fig. 22, demonstrated that W02 had a strong effect on IkBo. level in the higher concentration used (200 pg/mL), which could be compared to the effect of parthenolide. Therefore, it was suggested that W02 exerts a mode of action similar to that of parthenolide (PAR), namely, affecting IkBa phosphorylation. However, W02 appeared to be a stronger inhibitor of IxBo degradation than the other mushrooms tested: Leucoagaricus birnbaumii (LB12 — mycelial ethyl acetate extract), Tricholomopsis sulphureoides (TS03- mycelial
J
BN ethyl alcohol extract), Pleurotus ostreatus (POO1-mycelial diethyl ether extract), and Schizophyllum commune (SCO1- mycelial diethyl ether extract).
In order to prove the phosphorylation inhibitory activity of W02, it was tested as a modulator of p-IkBa level. Results showed that W02 acts as a strong inhibitor of IxBa phosphorylation in both concentrations used and its effect might be considered as similar to the effect of parthenolide (Fig. 23). 5.11 Effect of W02 Ganoderma tsugae var. jannieae strain Tay-1 extract on cell survival dependency on NF-xB pathway. Cancer cell lines vary in their dependency on the NF-kB pathway for their survival. Parthenolide, a NF-kB inhibitor, was used in order to evaluate the utilization of NF-kB pathway by various cancer cell lines for their survival.
The effect of Ganoderma tsugae var. jannieae W02 mushroom extract was compared on the one hand to that of partenolide (PAR), which was used as a control, and on the other, to that of another active Fomes fomentarius mushroom extract, FF04. The latter was obtained after extraction of the culture liquid of
Fomes fomentarius with ethyl acetate and also demonstrated a strong inhibitory effect on IxBa phosphorylation in the luciferase reporter gene assay (data not shown).
Five different cancer cell lines, MCF7, Baf3/p185 Bcr-Abl, 9L, DU145, and
PC3 were treated with increasing concentrations of parthenolide (1, 5, 10, and 20 uM) and with the selected mushroom extracts. For each cell line, independently, the ICs, values of parthenolide were determined as well as the ICsgs of each extract tested (Fig. 24). Consequently, the effectiveness of the fungal extracts on each cell line was considered relative to the effect of parthenolide on the same cell line. Due to the fact that different cancer cells exert different stability, the ICso values obtained for parthenolide as well as for the extracts varied. However, in all cell lines used, except MCF7, W02 extract showed stronger effect on cell viability than : the FFO4. 42
Co oo {
Results showed that the laboratory model of CML, Baf3/p185 Bcer-Abl, was the most sensitive cell line to parthenolide, with the lowest ICs (3.2 pM or 0.79 pg/mL). This cell line appeared to be the most sensitive also to the two extracts tested (Fig. 24). Among the other tested cell lines, PC3, androgen-independent cancer cell line, appeared to be the least sensitive to parthenolide, followed by
DU145, androgen-independent cancer cell line, 9L, rat glioblastoma cell line, and
MCF7, breast cancer cell line. However, considering the extracts’ effects, W02 showed a stronger activity in all the cell lines used, except in MCF7 with ICs of 220 pg/mL. In 9L cell line the two extracts exhibited almost equal effects (ICsq of 120 pg/ml for FF04, and ICs of 117 pg/mL for W02), while in Baf3/p185 Ber-Abl,
DU145, and PC3, W02 appeared to be much more active with ICs; of 35, 78, and 110 pg/mL, respectively. These results suggest that W02 might affect the cell viability in a similar way to that of parthenolide, although it appeared to be less effective.
Aggarwal B.B. 2004. Nuclear factor-kB: the enemy within. Cancer Cell, 6:203-208.
AOAC. 1990. Official Methods of Analysis, 15th ed. Association of Official
Analytical Chemists, Washington, DC.
Boh B. and Berovic M. 2007. Grifola frondosa (Dicks.:Fr) S.F.Gray (maitake mushroom): medicinal properties, active componds, and biotechnological cultivation. Int J Med Mushr, 9:89108.
Borchers A.T., Keen C. L., and Gershwin M. E. 2004. Mushrooms, tumors, and immunity: an update. Exp Biol Med, 229: 393-406.
Braaten J.T., Wood P.J., Scott F.W., Wolynetz M.S., Lowe M.K., Bradley-
White P. and Collins M.W. 1994. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur J Clin Nutr, 48: 465-474.
Brennan C.S. and Cleary L.J. 2005. The potential use of cereal (1 -> 3,1 -> 4)-beta-D-glucans as functional food ingredients. J Cereal Science, 42: 1-13.
Brown G.D. and Gordon S. 2001. Immune recognition. A new receptor for
B-glucans. Nature, 413:36-37.
Brown G.D. and Gordon S. 2005. Immune recognitionof fungal B-glucans.
Cellular Microbiology, 7:471-479.
Burits M. and Bucar F. 2000. Antioxidant activity of Nigella sativa essential oil. Phytotheraphy Research, 14: 323-328.
Chang S.T. and Buswell J.A. 2003. Medicinal mushrooms- a prominent source of nutriceuticals for the 21% century. Curr Tropics Nutraceut Res, 1:257- 280.
Chen J. and Seviour R. 2007. Medicinal importance of fungal $-(1-3),(1-6)- glucans. Mycol Res, 111:635-652.
Chihara G., Maeda Y., Hamuro J, Sasaki T., and Fukuoka F. 1969.
Inhibition of mouse Sarcoma 180 by polysaccharides from Lentinus edodes (Berk.)
Sing. Nature, 222:687-688. “
Duus I., Gotfodsen C.H., and Bock K. 2000. Carbohydrate structural ] determination by NMR spectroscopy: modern methods and limitations. Chemical
Reviews, 100: 4589-4614
Hobbs Ch. 1995. Medicinal mushrooms. An exploration of tradition, healing, & culture. Interweare Press, Inc., Loveland, CO, USA.
Hong F., Yan J., Baran J.T., Allendorf D.J., Hansen R.D., Ostroff G.R.,
Xing P.X., Cheung NK., and Ross G.D. 2004. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol, 173:797-806.
Kataoka K., Muta T., Yamazaki S., and Takeshige K. 2002. Activation of macrophages by linear (1-3)-B-D-Glucans. J Biol Chem, 277: 36825-36831
Kikumoto S. and Kimura K. 1971. Polysaccharide produced by
Schizophyllum commune. Partll. Chemical structure of an extracellular polysaccharide. J of Agricult and Chemical Soc Japan, 45:162-168.
Lindequist U., Niedermeyer T.H.J., and Julich W. D. 2005. The pharmocological potential of mushrooms. eCAM, 2:285-299.
Luhm J., Langenkamp U., Hensel J., Frohn Ch., Brand J.M., Hennig H.,
Rink L., Koritke P., Wittkopf N., Williams D.L., and Mueller A. 2006. B-(1—3)-D- glucan modulates DNA binding of nuclear factors kB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1P/IL-1 receptor antagonist ratio. BMC
Immunology, 7:5.
Lull C., Wichers H.J., and Savelkoul H.F.J. 2005. Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators of Inflammation, 2: 63-80.
Misaki A., Kakuta M, Sasaki T., Tanaka M., and Miyaji H. 1981. Studies on interrelations of structure and antitumor effects of polysaccharides: antitumor action of periodate-modified, branched (1—3) B-D-glucan of Auricularia auricular- judae, and other polysaccharides containing (1—3)-glycosidic linkages. Carbohydr
Res, 92:113-129.
CL
Mizuno T. 1999. The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan. Int J Med Mushr, 1: 9-30.
Mizuno T., Wang G., Zhang J., Kawagishi H., Nishitoba T., and Li J. 1995.
Reishi, Ganoderma lucidum and Ganoderma tsugae: bioactive substances and medicinal effects. Food Rev Int, 11:151-166.
Moncalvo J-M. 2005. Molecular systematics of Ganoderma: what is reishi?
Int J Med Mushr, 7:353-354.
Moncalvo J-M. and Ryvarden L. 1997. A nomenclatural study of the
Ganodermataceae. Fungiflora, Oslo. 114 pp.
Moradali M-F., Mostafavi H., Ghods Sh., and Hedjaroude G-A. 2007.
Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int Immunopharmacology, 7:701-724.
Nauts H.C., Swift W.E., and Colley B.L. 1946. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, reviewed in the light of modern research. Cancer Res, 6:205-214.
Petrova R.D., Reznick A.Z., Wasser S.P., Denchev C.M., Nevo E., and
Mahajna J. 2008. Fungal metabolites modulating NF-kB activity:an approach to cancer therapy and chemoprevention (review). Oncology Report, 19:299-308.
Sevag M.G., Lackman D.B., and Smolens J. 1938. The Isolation of the components of ctreptococcal nucleoproteins in serologically active form. J. Biol.
Chem. 124, 425-436.
Sliva D. 2003. Ganoderm lucidum (reishi) in cancer treatment. Integr
Cancer Ther, 2:358-364.
Storseth T.R., Hansen K., Reitan K.I., and Skjermo J. 2005. Structural characterization of beta-D-(1-->3)-glucans from different growth phases of the marine diatoms Chaetoceros mulleri and Thalassiosira weissflogii. Carbohydr.
Res, 340: 1159-1164.
Sullivan R., Smith J.E., and Rowan N.J. 2006. Medicinal mushrooms and cancer therapy. Perspectives in Biology and Medicine, 49:159-170. i
Wang G., Zhang J, Mizuno T., Zhuang C., Ito H., Mayuzumi H., Okamoto
H., and Li J. 1993. Antitumor active polysaccharides from the Chinese mushroom songhan LingZhi, the fruiting body of Ganoderma tsugae. Biosci Biotechnol
Biochem, 57:894-900. : Wasser S.P. and Weis A.L. 1999. Medicinal properties of substances occuring in higher Basidiomycetes mushrooms: Current perspectives [Review]. Int
J Med Mushr, 1: 31-62
Wasser S. P., Nevo E., Sokolov D., Reshetnikov S., and Timor-Tismenetsky
M. 2000. Dietary supplements from medicinal mushrooms: diversity of types and variety of regulations. Int J Med Mushr, 2: 1-19.
Wasser S. P., Sokolov D., Nevo E., Reshetnikov S., and Timor-Timenetsky
M. 2001. Dietary supplements from medicinal mushrooms: How we are going to ensure their quality and safety. Int J Med Mushr, 3: 94.
Wasser S. P. 2002a. Review of medicinal mushrooms advances. Good news from old allies. Herbalgram, 56: 29-33
Wasser S. P. 2002b. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol, 60:258-274
Wasser S.P., Didukh M.Y., and Nevo E. 2004. Dietary supplements from culinary-medicinal mushrooms: a variety of regulations and safety concerns for the 21st century. Int J Med Mushr, 6: 231-248.
Wasser S. P., Zmitrovich I. V., Didukh M. Y. Malysheva V. F. 2006. New medicinal Ganoderma mushroom from China: G. fsugae Murrill var. jannieae var. nov. (Aphyllophoromycetideae). Int J Med Mushr, 8: 161-172
Wu X.L. and Dai Y.V. 2005 Coloured illustrations of Ganodermataceae in
China. Science Press, Beijing. 229 pp. (in Chinese)
Yap A-T. and Ng M-L.M. 2001. An improved method for the isolation of lentinan from the edible and medicinal Shiitake mushroom, Lentinus edodes (Berk.)
Sing. (Agaricomycetideae). Int J Med Mushr, 3: 9-19. a7 i
Yuen JJW.M and Gohel M.D.I. 2005. Anticancer effect of ganoderma lucidum: a review of scientific evidence. Nutrition and Cancer, 53:11-17.
Zaidman B.-Z, Wasser S.P., Nevo E., and Mahajna J. 2007. Androgen receptor-dependent and —independent mechaisms mediate Ganoderma [lucidum activities in LNCaP prostate cancer cells. Int J Oncol, 31:959-967.
Zhang L., Li X., Xu X., and Zeng F. 2005. Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr Res, 340, 1515-1521.
Zhang J., Wang G., Li H., Zhuang C., Mizuno T., Ito H., Mayuzumi H.,
Okamoto H., Li J. 1994. Antitumor active protein-containing glycans from the
Chinese mushroom Songhan LingZhi, Ganoderma tsugae mycelium. Biosci
Biotechnol Biochem, 58:1202-1205
Zhang M., Cui S.W., Cheung P.CK., and Wang Q. 2007. antitumor . polysaccharides from mushrooms: a review on their isolation process, structural characteristics and antitumor activity. Trends in Food Sci & Technol, 18:4-19.
Zhang Q.H., and Lin Z.B. 1999. The antitumor activity of Ganoderma lucidum (Curt.:Fr) P Karst. (Ling Zhi) (Aphyllophoromycetideae) polysaccharides.
Int J Med Mushr, 1:207-215. ! , ee Ce Co i
Claims (26)
- CLAIMS:I. A PB-glucan composed of a backbone structure of B-1-3- and B-I-4-linked D- glucopyranose residues bearing, at some of the 6-positions, side chains of B-1-6-D- glucopyranose residues, of the structure: B-D-Glep-(1-{-6)-B-D-Glep-(1-Jo.1] -[-3)-B-D-Glep-(1-]iow[-4)-B-D-Glcp-(1-Jeu-[-3)-B-D-Glep-(1-Isy-[-4)-B-D-Glop-(1-]y- B-D-Glep-(1-[-6)-B-D-Glep-(1-Jo.1 wherein Glcp represents a glucopyranose residue and n is an integer equal to or larger than 1.
- 2. The B-glucan of claim 1 having a molecular weight of less than 10,000 Da.
- 3. The B-glucan of claim 2 having a molecular weight of about or less than 5,000Da.
- 4. The B-glucan of claim 1, obtained from Ganoderma tsugae var. jannieae.
- 5. The B-glucan of claim 1, obtained from dried fruiting bodies of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394.
- 6. The B-glucan of claim 1, obtained from submerged cultivated mycelium of Ganoderma tsugae var. jannieae strain Tay-1 CBS 120394.
- 7. A composition comprising a 3-glucan as defined in any of claims 1 to 6.
- 8. The composition of claim 7, for use as a nutriceutical composition.
- 9. The composition of claim 8, formulated in an oral solid dosage form.
- 10. The composition of claim 9, wherein said oral solid dosage form is selected from a fine powder, capsules, tablets, caplets, and sachets.
- 11. The composition of claim 8, formulated into a food products.
- 12. The composition of claim 8, formulated into a pet food products.
- 13. The composition of 8, formulated into a beverage products.
- 14. The composition of 13, formulated into an energizing beverage products.
- 15. The composition of claim 8, formulated into a cosmetic products.
- 16. The composition of claim 15, wherein said cosmetic product is selected from an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve or an ointment.
- 17. The composition of any one of claims 7 to 10, for use as a dietary supplement.
- 18. The composition of claim 8, for stimulation of the immune system.
- 19. The composition of claim 18, for use as adjuvant to chemotherapy or radiotherapy of tumors.
- 20. The composition of claim 18, for prevention and treatment of bacterial, parasitic or viral infections.
- 21. The composition of claim 18, for treatment of human immunodeficiency virus (HIV) infection.
- 22. The composition of claim 7, for use in treatment of an NF-kB-dependent diseases.
- 23. The composition of claim 22, wherein said NF-«kB-dependent disease is selected from cancer, immunological disorders, septic shock, transplant rejection, radiation damage, reperfusion injuries after ischemia, arteriosclerosis, osteoporosis, and neurodegenerative diseases.
- 24. The composition of claim 8, for lowering levels of total cholesterol and LDL cholesterol.
- 25. The composition of claim 24, for prevention of cardiovascular diseases.
- 26. The composition of claim 8, for control of blood sugar levels and reduction of glycemic index in Type II diabetic patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95301107P | 2007-07-31 | 2007-07-31 | |
PCT/SG2008/000278 WO2009017463A2 (en) | 2007-07-31 | 2008-07-30 | NOVEL β-GLUCANS ISOLATED FROM HIGHER BASIDIOMYCETES MUSHROOM GANODERMA TSUGAE VAR. JANNIEAE |
Publications (1)
Publication Number | Publication Date |
---|---|
SG174111A1 true SG174111A1 (en) | 2011-10-28 |
Family
ID=40305080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2010054831A SG174111A1 (en) | 2007-07-31 | 2008-07-30 | NOVEL ß-GLUCANS ISOLATED FROM HIGHER BASIDIOMYCETES MUSHROOM GANODERMA TSUGAE VAR. JANNIEAE |
Country Status (2)
Country | Link |
---|---|
SG (1) | SG174111A1 (en) |
WO (1) | WO2009017463A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
JP2020500860A (en) | 2016-11-23 | 2020-01-16 | ゴジョ・インダストリーズ・インコーポレイテッド | Disinfectant compositions containing probiotic / prebiotic active ingredients |
CN108969530A (en) * | 2017-05-31 | 2018-12-11 | 三华生物科技股份有限公司 | A kind of polysaccharide mixture is used to prepare the purposes of hyperglycemia drug |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100347196C (en) * | 2004-06-29 | 2007-11-07 | 长春市恒泰生物技术有限公司 | Ganodema tsugae-proteoglycan and its preparing method and use |
-
2008
- 2008-07-30 WO PCT/SG2008/000278 patent/WO2009017463A2/en active Application Filing
- 2008-07-30 SG SG2010054831A patent/SG174111A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009017463A2 (en) | 2009-02-05 |
WO2009017463A3 (en) | 2009-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhu et al. | Beta-glucans from edible and medicinal mushrooms: Characteristics, physicochemical and biological activities | |
Li et al. | Purification, characterization and immunomodulatory activity of a novel polysaccharide from Grifola frondosa | |
Kothari et al. | Anticancer and other therapeutic relevance of mushroom polysaccharides: A holistic appraisal | |
Du et al. | Structural characterization and immunomodulatory activity of a novel polysaccharide from Ficus carica | |
Cateni et al. | Mycochemicals in wild and cultivated mushrooms: nutrition and health | |
Bi et al. | Structural elucidation and immunostimulatory activity of a new polysaccharide from Cordyceps militaris | |
Ferreira et al. | Chemical features of Ganoderma polysaccharides with antioxidant, antitumor and antimicrobial activities | |
Mei et al. | A novel polysaccharide from mycelia of cultured Phellinus linteus displays antitumor activity through apoptosis | |
Wang et al. | Characterization of a water-soluble polysaccharide from Boletus edulis and its antitumor and immunomodulatory activities on renal cancer in mice | |
Wei et al. | Structure characterization and immunomodulating effects of polysaccharides isolated from Dendrobium officinale | |
Yelithao et al. | Studies on structural properties and immune-enhancing activities of glycomannans from Schizophyllum commune | |
Huang et al. | The structure of mushroom polysaccharides and their beneficial role in health | |
Wang et al. | Structure and inducing tumor cell apoptosis activity of polysaccharides isolated from Lentinus edodes | |
Boh | Ganoderma lucidum: a potential for biotechnological production of anti-cancer and immunomodulatory drugs | |
Zhang et al. | Isolation and structure elucidation of polysaccharides from fruiting bodies of mushroom Coriolus versicolor and evaluation of their immunomodulatory effects | |
Wisitrassameewong et al. | Agaricus subrufescens: a review | |
Li et al. | Anti-tumor and immunomodulating activities of proteoglycans from mycelium of Phellinus nigricans and culture medium | |
Sarangi et al. | Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans | |
Bandara et al. | Polyporus umbellatus, an edible-medicinal cultivated mushroom with multiple developed health-care products as food, medicine and cosmetics: a review | |
Castro-Alves et al. | Characterization and immunomodulatory effects of glucans from Pleurotus albidus, a promising species of mushroom for farming and biomass production | |
Bhanja et al. | Water-insoluble glucans from the edible fungus Ramaria botrytis | |
Kozarski et al. | Dietary polysaccharide extracts of Agaricus brasiliensis fruiting bodies: chemical characterization and bioactivities at different levels of purification | |
Li et al. | Physicochemical characteristics and biological activities of polysaccharide fractions from Phellinus baumii cultured with different methods | |
WO2009017462A2 (en) | New ganoderma tsugae var. jannieae strain tay-i and biologically active biomass and extracts therefrom | |
CN104672339B (en) | Cordyceps cicadae rhzomorph as well as preparation method and application thereof |